Overview

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

Status:
Recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Cyclophosphamide
Fludarabine
Fludarabine phosphate